The World Cancer Research Fund International puts liver cancer sixth on the list of most common types of cancers that affect people globally. The organization states that in 2012, 782,000 new cases of liver cancer were diagnosed. The current market for liver cancer therapies faces a huge gap as the currently available drugs are not able to control the diseases completely. This naturally has led to the creation of a highly active and dynamic deals landscape for therapies for liver cancer.
The market for liver cancer has become more active in the last few years. According to the estimates of GBI research, in the eight-year period between 2006 and 2014, about 62 licensing deals have been inked in the liver cancer market. Estimates also show that about 23 co-development deals have been inked during the same time.
Despite the deals and co-development landscape showing much promise, there is a lot to be desired on the first-in-class products front. There aren’t enough deals in this domain to convince market watchers that first-in-class innovation will indeed be a cornerstone of the liver cancer market in the coming years.
Here are a few insights that lend more clarity to the liver cancer deals and co-development scenario:
· A comparative study of the various deals forged in the liver cancer therapies market shows that the deal values commanded by first-in-class products is much higher than those products that are not classified as first-in-class. By virtue of commanding a premium, first-in-class products demonstrate their important position in the liver cancer market.
· Market studies also show that about 68 such first-in-class products for treating liver cancer that are in the development stage currently, do not fall under the purview of any co-development or licensing deal.
· The opportunities for strategic collaborations and alliances abound. The liver cancer market is currently undergoing a transformation, and in its new avatar, it will be in favor of innovative and targeted liver cancer therapies that carry a strong clinical record. Opportunities for bolstering the portfolio of first-in-class therapies are many. So are those for funding clinical initiatives.
· Though not all therapies pertain to treating or addressing disease-causing pathways, many therapies are strongly supported by appreciable clinical and scientific data. This makes these therapies potentially lucrative investment opportunities while also making them promising candidates for therapeutics.
· Currently, market analysts note that the liver cancer therapeutics pipeline shows unmistakable signs of adapting to the increased understanding of abnormal signaling pathways as well as liver cancer causes. With treatments being increasingly aligned with certain disease-causing characteristics, the harmful cytotoxic effects can be curbed making therapies safer and more accurate.
Browse the full Press Release of Liver Cancer Market : http://www.mrrse.com/liver-cancer-market-report
While the potential offered by first-in-class products is promising, this in itself doesn’t guarantee success. The need for robust support in the form of preclinical and clinical data is a must.